MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
Healthcare
$53.42 -1.54%
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
52W Low $9.43High $45.85
Volume 0.73M
Average 0.65M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$79.95M
FY 2025 · Annual
Investing Cash Flow
-$83.70M
FY 2025 · Annual
Financing Cash Flow
$189.59M
FY 2025 · Annual
-19.0% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
| Change in Working Capital | 1.29M | (735K) | 4.6M | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 671K | 412K | 3.93M | (2.46M) |
| Other Working Capital | 619K | (1.15M) | 670K | 4.03M |
| Other Non-Cash Items | 1.36M | (880K) | (2.82M) | (3.48M) |
| Operating Cash Flow | (23.12M) | (31.98M) | (54.68M) | (79.95M) |
| Capital Expenditures | (441K) | (129K) | (874K) | (1.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.22M) | (63.8M) | (239.47M) | (358.15M) |
| Sales of Investments | 9.25M | 33M | 79.75M | 267.87M |
| Other Investing Activities | 0 | 0 | 0 | 8.5M |
| Investing Cash Flow | (11.41M) | (30.93M) | (160.6M) | (83.71M) |
| Debt Repayment | 10M | 0 | 0 | 0 |
| Common Stock Issued | 30K | 739K | 174.54M | 189.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (428K) | (30K) | (3.94M) | 0 |
| Financing Cash Flow | 46.06M | 69.22M | 234.1M | 189.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
| Free Cash Flow | (23.56M) | (32.11M) | (55.56M) | (81.88M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$87.0M
+ D&A$248.0K
+ Stock-Based Comp$8.7M
+ Deferred Tax$0
+ Working Capital$1.6M
- Other Non-Cash-$3.5M
= Operating Cash Flow-$79.9M
- Capex-$1.9M
= Free Cash Flow-$81.9M
Analysis
FY2025 free cash flow is -$81.9M. FCF conversion is 94.1% of net income. Operating cash flow was -$79.9M, with capex of -$1.9M. The largest bridge item is Stock-Based Comp at $8.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-8 | S-8 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
Does MBX generate free cash flow?
MBX Biosciences, Inc. Common Stock (MBX) generated -$81.88M of free cash flow in fiscal 2025.
How much operating cash flow does MBX produce?
Operating cash flow was -$79.95M, before capital expenditures of $1.93M.
Continue the stock analysis
Jump to another research area for this company.